On July 28, IQVIA rose 10.21% in regular trading, trading at $235.0/share, with turnover of $15.98 million. The surge was driven by the company's Q2 earnings release, which exceeded expectations on all key metrics alongside an upward revision to full-year guidance.

Specifically, IQVIA reported Q2 adjusted EPS of $3.15, beating the consensus estimate of $3.03 by 3.96% and representing a 12.1% year-over-year increase from $2.81. Revenue came in at $4.37 billion versus the $4.30 billion expected, up from $4.02 billion a year earlier. The company raised its full-year adjusted diluted EPS guidance to $12.80-$13.00, up from the prior range of $12.65-$12.95, and lifted revenue guidance to $17.28-$17.48 billion from $17.15-$17.35 billion previously.

Heading into the report, multiple investment banks had raised their price targets in July, including Baird to $252, HSBC to $240, Mizuho to $230, and Leerink Partners to $240, all maintaining bullish ratings. Analysts had cited accelerating organic growth, AI tailwinds, and patent cliff-driven CRO demand as positive catalysts.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)